Business Wire

NY-ESTÉE-LAUDER

4.3.2021 13:02:17 CET | Business Wire | Press release

Share
The Estée Lauder Companies Announces New Equity and Engagement Center of Excellence

The Estée Lauder Companies (NYSE:EL) announced today that it has established a new Equity and Engagement Center of Excellence (COE). The creation of this new capability underscores The Estée Lauder Companies’ (ELC) core values and commitments to build greater equity and representation within every aspect of its business, from its employees to its consumers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005218/en/

The Equity and Engagement COE will be led by Nicole Monson , who has been appointed Senior Vice President, Equity and Engagement. Nicole will report directly to Michael O’Hare, Executive Vice President, Global Human Resources.

The events of 2020 and the movement around racial equality have placed a necessary spotlight on every company’s responsibility to take action to advance equal representation, advocacy and inclusion across their organizations. From examining and evolving how the company engages with employees around the world, to enabling greater collaboration across its brands, regions and functions, ELC remains dedicated to purposeful, strategic and accelerated action to drive lasting change.

Building upon ELC’s existing Commitment to Act on Racial Equity , actions on pay equity and other activities to date, the creation of the Equity and Engagement COE signals ELC’s investment in a focused and holistic approach to drive sustainable progress and advance the company’s diverse talent through deep engagement, career advancement, development programs, hiring practices and beyond.

“Our collective vision is to be the most inclusive, equitable and diverse global prestige beauty company for our employees and consumers alike. This important new capability will enhance employee engagement and build greater equity across the business today, while also providing a strategic platform to expand and scale this work into the future,” said Fabrizio Freda, President and Chief Executive Officer . “We know that authentic change takes time, dedication and a clear strategy, and we will continue to devote focused and meaningful resources toward accelerating this goal.”

“Since our company’s founding, our talented employees have been at the center of our business and the most important driver of our success. While we are proud of the progress we have made as a company thus far, we are committed to driving equity and engagement for the long-term,” said William P. Lauder, Executive Chairman . “Nicole’s deep experience and extensive knowledge of Human Resources and the global legal environment, combined with her demonstrated ability to positively influence ELC’s culture, have been invaluable to the company. I look forward to her continued leadership at the helm of this new Center of Excellence.”

As Senior Vice President, Equity and Engagement, Nicole will be an important member of ELC’s Senior Leadership Team and she will work across all areas of the business to develop the company’s long-term Equity and employee Engagement strategy and enterprise-wide capabilities. She will lead the development and implementation of proactive Equity and Engagement initiatives to create a workforce that is more representative and responsive to people of all backgrounds, where all have an opportunity to succeed.

The Equity and Engagement COE was designed to be a strategic and complementary enterprise-wide partner to ELC’s other leaders and business units focused on ESG-related matters, including Human Resources, the Inclusion, Diversity & Equity (IDE) COE, Global Communications, Global Citizenship and Sustainability (GCCS), Global Public Affairs, and beyond. In this spirit, Nicole will collaborate closely with Human Resources leaders and the IDE COE to develop programs designed to ensure fair, inclusive, and equitable treatment of employees around the world with emphasis on addressing conflict and implementing support systems for employees of color, ensuring equitable compensation, application of policies and access to career paths and ensuring the execution of ELC’s equity and engagement vision and strategy. Additionally, Nicole will lead the company’s Racial Equity Initiative, which includes finalizing and implementing a strategy to ensure ELC achieves its Racial Equity Commitments.

Nicole has an extensive proven track record of providing business partners with strategic legal counsel on a wide range of employment and compliance topics, a background that will serve her well in her new role. In her most recent position as Senior Vice President, Deputy General Counsel, Global Employment, Ethics and Legal Privacy, Nicole oversaw the Employment Law, Ethics and Legal Privacy teams and worked to advance the Legal strategy for employment, ethics and privacy globally to protect the company’s interests and mitigate risks associated with new laws and regulations, growth of digital platforms, new global acquisitions and an increased regulatory environment. Since joining the company in 2014 as Vice President, Employment Counsel, her role has continuously expanded and evolved with new responsibilities.

Nicole’s influence on ELC’s organizational culture has extended far beyond her official role and responsibilities. As a member of ELC’s Diversity Council, as well as ELC’s ‘Network of Black Leaders & Executives’ and ‘Women’s Leadership Network’ Employee Resource Groups, Nicole has long been passionate about promoting a culture of respect, inclusivity and belonging. Recently, she became Executive Sponsor of She’s Howard: Own Your Power , ELC’s partnership with Howard University to support the success of the University’s alumnae through experiential learning, career coaching, professional training and self-empowering mentorship opportunities.

In addition to her many contributions to ELC, Nicole is a highly regarded expert and thought leader. She has been a guest speaker for numerous local and national organizations. Notably, Nicole was also selected for inclusion into the National Black Lawyers Top 100 , an elite network of successful and influential lawyers with reputations for providing excellent legal representation in their respective practice areas.

Nicole has more than 20 years of relevant experience across labor and employment law and compliance. She earned her J.D. from Howard University School of Law and her B.A. from Spelman College.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.

ELC-C
ELC-L

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye